Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OVADER: Eliapixant in Overactive Bladder (OAB)
NCT04545580Phase 2Completed
- Sponsor
- Bayer
- Start
- Sep 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of eliapixant in overactive bladder (OAB), sponsored by Bayer. Started Sep 2020; status: completed.
02
Drugs
eliapixant
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT04545580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04545580.